Pozen MT 100 Benefit In Migraine Does Not Outweigh Tardive Dyskinesia Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Peripheral & Central Nervous System Drugs Advisory Committee says additional studies of the naproxen/metoclopramide product must show an effect on two-hour pain-free response.
You may also be interested in...
Trexima NDA Filing Relieves Pozen’s MT 100 Headache
Acceptance of the NDA filing will trigger a $20 mil. milestone payment from GlaxoSmithKline.
Trexima NDA Filing Relieves Pozen’s MT 100 Headache
Acceptance of the NDA filing will trigger a $20 mil. milestone payment from GlaxoSmithKline.
Pozen Discontinues MT 100, Shifts Focus To Trexima NDA Filing
MT 100 U.S. development abandoned one day after FDA advisory committee recommends additional studies for the migraine product.